Mass General, Harvard to Use Illumina Genotyping Tech in Large ALS Study | GenomeWeb
NEW YORK (GenomeWeb News) – Illumina today said researchers from Massachusetts General Hospital and Harvard Medical School will use data from its Sentrix HumanHap300 BeadChips and Infinium assay reagents to run a whole-genome association study of amyotrophic lateral sclerosis.
 
The 2,200-sample case/control study is the largest genetic study to date of ALS, according to study co-supervisor Adrian Ivinson, director of Harvard’s Center for Neurodegeneration and Repair.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.